Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00101985
Recruitment Status : Completed
First Posted : January 19, 2005
Last Update Posted : April 13, 2015
Information provided by (Responsible Party):

January 18, 2005
January 19, 2005
April 13, 2015
October 2004
July 2005   (Final data collection date for primary outcome measure)
Determine whether talnetant provided adequate relief from IBS pain and discomfort for at least one of three talnetant dose groups compared with placebo and to determine the safety and tolerability of talnetant in subjects with IBS.
Not Provided
Complete list of historical versions of study NCT00101985 on Archive Site
- Explore response among subgroups IBS. - Evaluate positive treatment effects within bowel subgroups. - Compare treatment groups for global improvement of IBS symptoms. - Improvement of IBS pain or discomfort, Quality of Life.
Not Provided
Not Provided
Not Provided
Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)
An Eight-week, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects With Irritable Bowel Syndrome
This study will evaluate the effectiveness and safety of the investigational drug talnetant in treating subjects with irritable bowel syndrome (IBS).
Not Provided
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Irritable Colon
Drug: talnetant
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
July 2005
July 2005   (Final data collection date for primary outcome measure)

Inclusion criteria:

  • Subjects will be required to conduct self-assessments of their IBS symptoms using a touch-tone telephone system for the duration of the study (15 weeks).
  • Must be diagnosed with IBS consistent with the Rome II criteria.
  • Must have normal results from a colonic procedure within 2 years of randomization.
  • Must have conducted self-assessments on at least 12 days and have a documented average IBS pain or discomfort score of greater than or equal to 1.5 during the two-week screening phase.

Exclusion criteria:

  • Self-assessment of no stool for 7 days during the two-week screening phase.
  • Clinically significant abnormal laboratory tests.
  • Current evidence or history of various conditions, comorbidities, or surgeries such as Irritable Bowel Disease (IBD), gastrointestinal surgeries, and diverticulitis.
  • Inability to use the touch-tone telephone system.
  • Hypersensitivity to quinolone antibiotics or quinolone derivatives.
  • Diagnosis of a psychiatric disorder within the past 2 years and not on a stable dose of medication for at least 6 months.
  • Women who are pregnant, breast feeding, or planning to become pregnant during the study.

Permitted medications: The subject is allowed to take any of the following medications, provided they maintain a stable dose for at least 30 days prior to the Screening visit and throughout the remainder of the study:

  • Antidepressants, except REMERON
  • Antihypercholesterolemics
  • Iron supplements
  • Bulking agents
  • Fiber supplement
  • Thyroid replacement therapy (levothyroxine)
  • Antipsychotics
  • Cox-2 inhibitors (CELEBREX)

Prohibited medications: Subjects must stop taking any medications they are taking to treat their IBS symptoms and must not have taken any of the prohibited medications at least 7 days prior to the Screening visit and must remain off these medications for the duration of the study.

  • Anticholinergics (dicyclomine, hyoscyamine, propantheline)
  • Cholinomimetic (bethanechol, pyridostigmine, tacrine, physostigmine)
  • All narcotics (morphine, codeine, TYLENOL #3, propoxyphene, either alone or in combination)
  • Tramadol hydrochloride (ULTRAM)
  • Colchicine
  • Orlistat (XENICAL)
  • Misoprostol, alone or in combination (ARTHROTEC, CYTOTEC)
  • 5-HT3 receptor antagonists (ondansetron, tropisetron, dolasetron, granisetron, mirtazapine, cilansetron, alosetron)
  • Tegaserod (ZELNORM)
  • Gabapentin
  • Lupron
  • Antacids containing magnesium or aluminium
  • Antidiarrheal agents
  • Bismuth compounds
  • Prokinetic agents (cisapride, metoclopramide)
  • Sulfasalazine
  • Laxatives
  • Cholestyramine
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Australia,   Canada,   France,   Germany,   Netherlands,   South Africa,   Spain,   Sweden,   United Kingdom,   United States
Not Provided
Not Provided
Not Provided
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
April 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP